On November 30, at the first China (Macao) International High-quality Consumption Expo and Hengqin World Bay Area Forum, the "First Hengqin World Bay Area Forum Biomedical Forum and 2022 China Big Health Industry Summit" was grandly held, guided by Southern Finance All Media Group, 21st Century Business Herald and 21st Century New Health Research Institute. Representatives from regulatory agencies, industry experts, industry representatives, investment institutions and other parties, focused on the theme of "Innovating high-quality development and accelerating the internationalization of medicine", and deeply focused on major changes in China's medical and health industry, Bay Area biopharmaceutical industry clusters, survival and development of innovative pharmaceutical companies, and the construction of "Healthy Bay Area" to explore the future together. At the
meeting, the 21st Century New Health Research Institute released the results of the "China Digital Medical Industry Development Trend Report (2022 Edition)" and the selection results of the "Healthy China 21CC Cancer Focus". In addition, the 2022 "Sunshine" Case Honor List of 21st Century Big Health Industry Competitiveness Research was also released.
Forum on-site
shapes the "Healthy Bay Area" and accelerates the development of the health industry
In recent years, with the comprehensive and in-depth implementation of the "Healthy China" strategy, my country has gradually established a scientific supervision system for the entire life cycle. Guided by clinical needs, the review and approval process has been continuously accelerated. With multiple favorable benefits such as policy encouragement, corporate efforts, and capital assistance, biomedicine has become the fastest-growing field in the current pharmaceutical and health industry.
For Guangdong-Hong Kong-Macao Greater Bay Area , the innovative and high-quality development of the biomedicine and big health industries has attracted much attention and expectations. Gui Yi, director of the Development Planning Department of the Planning and Information Department of the National Health Commission, said in his speech that shaping the "Healthy Bay Area" and accelerating the development of the health industry are key areas for the construction of the Guangdong-Hong Kong-Macao Greater Bay Area. Hengqin is one of the major platforms clearly defined in the "Hong Kong-Macao Greater Bay Area Development Plan Outline ". It has unique location advantages, dense capital and talents, and undertakes major tasks such as building a traditional Chinese medicine science and technology industrial park. It will surely become a display window and experimental field for promoting the high-quality development of local medical products and going to the world.
market has cooled down, and pharmaceutical innovative enterprises are facing three major challenges
Entering 2022. Under the influence of multiple uncertain factors, the biomedical investment and financing market has cooled down significantly, and many innovative enterprises have begun to adjust and prepare to "winter". How to view the development path of Chinese pharmaceutical innovative enterprises has also become a focus of attention.
Mao Hua, partner and managing director of Frost Sullivan Consulting Co., Ltd., said at the forum that the number of Chinese medical companies listed globally in 2021 is gradually increasing, and the speed of listing slows down in 2022. As of now, most unprofitable companies choose to list in Hong Kong. Judging from the current development of pharmaceutical innovative enterprises, we will face three major challenges: product homogeneity, , fierce price competition and serious talent loss.
"Specifically, in terms of product layout, the high enthusiasm of in China's pharmaceutical capital market has caused the current explosion of innovative drugs in China, but China's weak basic medical research capabilities have also led to insufficient basic R&D capabilities; at the same time, in terms of commercialization, the limited payment capacity of Chinese patients and the pressure of price reduction in medical insurance negotiations have affected the company's continuous profitability; in addition, in terms of team needs, Biotech is eager to recruit professional executive talents, but how to quickly adapt to corporate culture , leveraging the advantages of talents and retaining talents is another key proposition.
focuses on original innovation to achieve high-quality development of the industry
0 National regulatory level has successively introduced new policies to guide enterprises since the end of last year to promote the return of corporate R&D to clinical value. At the same time, the capital market has also begun to to , and investment tends to be rational.
It can be said that at present, China's biomedicine has reached a crossroads of development. If the original innovation is not increased, the first one will be anchored. In class drugs are being developed, then, China's biopharmaceutical industry still cannot escape the fate of low-level repeated competition and will only get further and further away from high-quality development.At the forum, guests such as "Director of Shenzhen Third Hospital and Academician of the American Academy of Microbiology" Lu Hongzhou , Zhang Jiancun, Chairman of Hengnuokang Pharmaceuticals, Jiang Haihua, Deputy General Manager of Beihai Bio, Shi Jianfeng, General Manager of Shengmei Bio, and other guests focused in-depth on the topic of "How to accelerate original innovation and promote the high-quality development of medicine?"
Experts believe that Chinese innovative pharmaceutical companies need to move from "general innovation 1.0" to "selected high-quality innovation 2.0", and seek innovative drugs with real clinical value in the gradually improved China's biomedical research and development ecosystem.
[Reporter] Ou Xujiang
[Author] Ou Xujiang
Healthy life circle
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-